NASDAQ NMS - GLOBAL MARKET · LXRX
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Pharmaceuticals
$1.76
Card
Relationship Map

Follow $LXRX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $LXRX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
LXRX
Lexicon Pharmaceuticals Inc
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

63/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is LXRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LXRX catalysts
About Lexicon Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2000
Employees
81
Country
US

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.76
Last session
Day high
$1.76
Last session
Day low
$1.76
Last session
Previous close
$1.76
52W high
$2.64
-33.33% from high
52W low
$1.14
41% of range
Market cap
$783.1M
EPS
$-0.1530
Beta
0.23
Shares out
445M
Avg volume
3M
VWAP
$1.76
Last session
Price history computed in-house
1W
-3.30%
1M
-21.08%
3M
-20.72%
1Y
+23.08%
YTD
+53.04%
SMA 50 $2.17 · below
SMA 200 $1.85 · below
52W position 41%

LXRX overview

Veridion Score
63
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LXRX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LXRX Form 4 filings
Public disclosures

Congress activity in LXRX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

LXRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LXRX in this window.
Lobbying spend

LXRX lobbying filings, year to date.

Registered lobbying filings matched to Lexicon Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LXRX in this window.
Loading news for LXRX
Analyst ratings
Sovereign unlock shows live analyst consensus for LXRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.